A-L Bienvenu, V Leray, C Guichon, S Bourget, C Chapuis, A Duréault, P Pavese, S Roux, E Kahale, W Chaabane, F Subtil, D Maucort-Boulch, F Talbot, X Dode, H Ghesquières, G Leboucher
BACKGROUND: Invasive aspergillosis (IA) is increasing especially in new groups of patients. Despite advances in management, morbidity and mortality related to IA remain high. Thus, Clinical Decision Support System (CDSS) dedicated to IA are needed to promote the optimal antifungal for each group of patients. PATIENTS AND METHODS: This was a retrospective multicenter cohort study involving intensive care units and medical units. Adult patients who received caspofungin, isavuconazole, itraconazole, liposomal amphotericin B, posaconazole, or voriconazole, for the treatment of IA were eligible for enrollment...
November 22, 2023: Annales Pharmaceutiques Françaises